Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference

Compugen (CGEN) will participate in a fireside chat and hold one-on-one investor meetings at the H.C.

Rhea-AI Summary

Compugen (CGEN) will participate in a fireside chat and hold one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference in New York City, held September 14-16, 2026.

The fireside chat is scheduled for Monday, September 14, 2026 at 3:30 PM ET, with a live webcast and replay available on the events page of Compugen’s Investor Relations website. Compugen is a clinical-stage cancer immunotherapy company using its AI-powered Unigen™ platform and is advancing an immuno-oncology pipeline that includes COM701 in an ovarian cancer trial, rilvegostomig being developed by AstraZeneca under an exclusive license, and GS-0321 licensed to Gilead and in a Phase 1 trial.

Key Figures

Fireside chat time: September 14, 2026 at 3:30 PM ET

Fireside chat time

September 14, 2026 at 3:30 PM ET

H.C. Wainwright Global Investment Conference

Key Terms

adaptive platform trial, anti-pvrig antibody, bispecific antibody, il-18 binding protein

4 terms

adaptive platform trial technical

"being evaluated in a blinded randomized ovarian cancer adaptive platform trial"

An adaptive platform trial is a flexible clinical study design that tests multiple treatments at once and adjusts which drugs, doses, or patient groups are pursued as results come in. Think of it like a single kitchen testing several recipes and quickly favoring the ones that work while dropping or changing the others — this can speed development, cut costs, and reduce risk for investors by identifying winners and failures faster than traditional one-at-a-time trials.

anti-pvrig antibody medical

"a potential first-in-class anti-PVRIG antibody"

An anti-PVRIG antibody is a laboratory-made protein designed to stick to and block PVRIG, a molecular “brake” on certain immune cells, so those cells can attack cancer more effectively. For investors, these antibodies matter because they are potential drug candidates: clinical trial results, safety, and regulatory decisions can strongly influence a developer’s prospects and share value, much like a new engine can change a car’s performance.

bispecific antibody medical

"a PD-1/TIGIT bispecific antibody"

A bispecific antibody is a specially designed protein that can attach to two different targets at the same time. Think of it as a custom-made connector that brings two things together—such as a disease cell and an immune system component—helping the body fight illnesses more effectively. For investors, understanding bispecific antibodies is important because they represent innovative therapies that could lead to new treatments and potentially lucrative market opportunities.

il-18 binding protein medical

"blocks the interaction between IL-18 binding protein and IL-18"

A naturally occurring protein that binds to the immune signaling molecule interleukin‑18 (IL‑18) and prevents it from activating immune cells. Think of it like a sponge or seatbelt that holds IL‑18 and stops it from triggering inflammation. It matters to investors because drugs or diagnostics that use or measure IL‑18 binding protein are common subjects of clinical trials and regulatory news that can affect the value of biotech companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOLON, Israel, Sept. 8, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced that management will participate in a fireside chat and hold one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference, being held from September 14-16 in New York City.

The fireside chat will be held on Monday, September 14, 2026 at 3:30 PM ET. A live webcast of the presentation will be available on the events page of the Investor Relations section of Compugen's website at www.cgen.com. A replay will be available following the live event.

Please contact your H.C. Wainwright representative for additional information or to schedule a meeting with Compugen.

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI-powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of COM701, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, is currently being evaluated in a blinded randomized ovarian cancer adaptive platform trial as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902, Compugen's anti-TIGIT antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that Compugen is conducting. In addition, Compugen has an early-stage immuno-oncology pipeline that consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company Contact:
Lindsey Trickett
Head of Investor Relations and Corporate Communications
Email: lindseyt@cgen.com
Tel: +1 (628) 241-0071

 

View original content:https://www.prnewswire.com/news-releases/compugen-to-participate-in-a-fireside-chat-at-the-hc-wainwright-28th-annual-global-investment-conference-302871939.html

SOURCE Compugen Ltd.

FAQ

How can investors access the Compugen fireside chat at the H.C. Wainwright conference?

A live webcast of the fireside chat, scheduled for September 14, 2026 at 3:30 PM ET, will be available on the events page of the Investor Relations section of Compugen’s website at www.cgen.com, and a replay will be available after the live event. Investors may contact their H.C. Wainwright representative for more information or to schedule a one-on-one meeting with Compugen.